• Molecular NameClavulanic_acid
  • SynonymClavulanate
  • Weight199.162
  • Drugbank_IDDB00766
  • ACS_NO58001-44-8
  • Show 3D model
  • LogP (experiment)-0.919
  • LogP (predicted, AB/LogP v2.0)-0.84
  • pka2.7
  • LogD (pH=7, predicted)-4.46
  • Solubility (experiment)300 mg/ml (potassium salt)
  • LogS (predicted, ACD/Labs)(ph=7)0.7
  • LogSw (predicted, AB/LogsW2.0)193.12
  • Sw (mg/ml) (predicted, ACD/Labs)1000.0
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds2
  • TPSA87.07
  • StatusFDA approved
  • Administrationoral, IV
  • PharmacologyA beta-lactamase inhibitor (marketed by GlaxoSmithKline, formerly Beecham) combined with penicillin group antibiotics to overcome certain types of antibiotic resistance. It is used to overcome resistance in bacteria that secrete beta-lactamase, which otherwise inactivates most penicillins.
  • Absorption_value75.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding22.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmhepatic (extensive)
  • Half life1 h
  • Excretionrenal (30–40%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityGastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients
  • LD50 (rat)N/A
  • LD50 (mouse)N/A